From Lab to Launch by Qualio
Qualio
All episodes
Best episodes
Seasons
Top 10 From Lab to Launch by Qualio Episodes
Goodpods has curated a list of the 10 best From Lab to Launch by Qualio episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to From Lab to Launch by Qualio for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite From Lab to Launch by Qualio episode by adding your comments to the episode page.
The physical effects of psychological trauma: with Dr. Eugene Lipov and Jamie Mustard
From Lab to Launch by Qualio
06/07/23 • 48 min
Is psychological trauma really just in the mind? Research suggests it isn't.
Today we’re interviewing two innovators on the front lines of life sciences and co-authors of a recent book.
Dr. Lipov has been called the “Einstein of modern anesthesiology” He’s a renowned board-certified pain specialist and a huge proponent of the stellate ganglion block, a minimally invasive procedure that has been proven effective in treating PTSD symptoms.
Jamie Mustard is an artist and a renowned strategic consultant. He is the author of the bestselling book “The Iconist: The Art and Science of Standing Out." Beginning as a child and then into adulthood he suffered years of trauma at varying levels before stumbling across Dr. Lipov and the Dual Sympathetic Reset Procedure or DSR.
Today we’re going to dive into their groundbreaking revelation that psychological trauma manifests as a physical injury that can be seen and monitored on a brain scan, and their revolutionary approach to resetting the sympathetic nervous system that has helped countless patients suffering from chronic pain, anxiety, PTSD, and other related conditions.
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Advancing Cancer Diagnostics with Mark McDonough, CEO of Chromacode
From Lab to Launch by Qualio
02/26/24 • 20 min
In this episode we interview Mark McDonough, the CEO of ChromaCode. The episode explores McDonough's journey to ChromaCode, from his early career as a naval officer to his roles at various medical and diagnostic companies. Under McDonough's leadership, ChromaCode has excelled in creating a high-definition PCR platform which enables fast, accurate, and affordable cancer diagnosis. The platform is particularly beneficial as it requires less patient tissue, provides rapid results, and has a lower cost than traditional diagnostic methods. McDonough also discusses the importance of partnerships in their go-to-market strategy and shared his insights on hiring and team development in today's competitive market. Looking ahead, ChromaCode expects to become a leader in developing innovative products for disease diagnosis, with a focus on patient-centered outcomes.
https://www.chromacode.com/
https://www.linkedin.com/in/mark-mcdonough-b1055216/
00:00 Introduction to the Podcast
00:40 Meet the Guest: Mark McDonough, CEO of ChromaCode
01:47 Mark's Journey to ChromaCode
06:05 Insights on Leadership and Building High Performing Teams
08:10 ChromaCode's Innovative Approach to PCR Testing
10:36 ChromaCode's Contribution to Precision Medicine
13:50 The Importance of Partnerships in ChromaCode's Strategy
16:33 Future Prospects for ChromaCode
18:27 Getting to Know Mark: Personal Interests
19:13 Closing Remarks and Contact Information
About Mark McDonough
Mark has over 25 years of experience helping build high growth HealthCare organizations. He is passionate about his team, his customers, and the patients that he and they are privileged to help serve. He most recently was the CEO of Pierian (now Velsera) which he led to a successful sale to Summa Equity, a private equity firm, in 2022. Prior to Pierian, he led CombiMatrix for five years, culminating in a sale to Invitae in 2017. Over his career, Mark has held various executive and commercial positions, and served as a US Naval Officer.
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
How to get to market faster with medical device outsourcing with Jeff Barrett, CEO of J-Pac Medical
From Lab to Launch by Qualio
10/26/22 • 30 min
We're excited to dive into the world of full-service medical outsourcing with Jeff Barrett, President and CEO OF J-Pac Medical. Jeff Barrett has more than 25 years of experience building high-growth medical product-based companies. He leads the advancement of J-Pac’s growth strategy, pursuing opportunities to further drive adoption of the company’s offerings and optimizing capabilities to better serve customers.
Prior to joining J-Pac Medical, Barrett held CEO positions at GI Supply and Optim LLC and Vice President of Operations roles at Haemonetics and Aspect Medical Systems. He is also a successful entrepreneur. By applying his operational and engineering aptitude, Barrett founded Eggrock Modular Solutions, which became a disruptive business in the building technology industry. Barrett has proven expertise building and managing high performance management teams, developing and implementing optimized operating infrastructure and manufacturing processes, and both improving existing product pipelines and growing new ones.
Barrett holds an MBA from Boston University’s Graduate School of Management, a B.S. in industrial engineering, and a B.A. in economics from Rutgers University.
About J-Pac Medical
J-Pac Medical has a 40-year track record of building industry partnerships based on trust, transparency, technical expertise and quality work above all else.
To learn more about our journey to becoming the unique full-service medical outsourcing provider we are today, read our company history here.
Show notes
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Eliminating Misdiagnosis of Sepsis with Greg Bullington, CEO of Magnolia Medical Technologies
From Lab to Launch by Qualio
10/27/23 • 26 min
Sepsis is often misdiagnosed, with approximately 40% of positive sepsis blood tests being incorrect. This leads to patients receiving unnecessary treatments, extended hospital stays, and risks associated with inaccurate diagnoses.
In this episode, Greg Bullington CEO of Magnolia Medical Technologies discusses the mission and innovations of Magnolia Medical Technologies, which is focused on improving the accuracy of sepsis diagnosis and reducing the overuse of antibiotics. Greg and his team have developed a technology to improve the accuracy of sepsis diagnosis and significantly reduce false positives.
The conversation touches on the challenges of bringing innovations to market, the importance of building a quality culture within the organization, and the future of blood culture testing. Greg emphasizes the need for evidence and the delivery of lower costs and better outcomes to gain support in the healthcare industry. He also discusses the role of non-dilutive funding sources and collaborations with key opinion leaders to drive innovation.
Magnolia Medical Technologies aims to continue solving the sepsis misdiagnosis problem and expand its reach. The company's vision includes developing additional solutions to improve diagnostic accuracy in various medical testing areas. Greg envisions a future with broader adoption of their technology, significantly reducing sepsis misdiagnosis and improving patient outcomes.
Guest Speaker Bio:
Greg Bullington is the co-founder and CEO of Magnolia Medical Technologies. Greg is an accomplished leader with a wide range of experience, having worked with senior executive teams in over 50 companies, ranging from Fortune 500 corporations to venture-backed startups. He's also an expert in intellectual property with numerous patents to his name. Greg's mission with Magnolia Medical Technologies is to eliminate the misdiagnosis of sepsis, a condition caused by blood infections and a leading cause of death, costs, and readmissions in hospitals nationwide.
Where to Learn More:
- Website: Magnolia Medical Technologies
- LinkedIn: Company Profile and Greg Bullington's Profile
This podcast episode provides valuable insights into the mission, innovations, and future goals of Magnolia Medical Technologies in the field of sepsis diagnosis. Listeners interested in healthcare innovation and improving patient outcomes will find this episode informative and engaging.
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Getting Treatments to Patients Faster by Focusing on Your Strengths with Keith Woods
From Lab to Launch by Qualio
03/29/23 • 20 min
There’s no question that 2022 was a tumultuous year for biotech companies. As 2023 is underway, we're talking to Keith Woods, former COO and current strategic advisor on the Commercial Committee of the argenx Board of Directors (from 3/13 on), a biotech company whose strong earnings come amid a downturn for the wider market and especially the biotech industry in 2022.
While other companies continue to face challenges in this climate, this biotech is hitting its stride – argenx has managed rapid growth, and a successful drug launch.
One major factor driving argenx’s success: argenx’s seasoned COO Keith Woods and his management philosophy of sustainable growth.
https://www.argenx.com/
https://www.linkedin.com/in/keith-woods-5b8b67117/
More about Keith
Keith is was COO since 2018 and is currently a strategic advisor on the Commercial Committee of the argenx Board of Directors (from 3/13 on). He comes with 25+ years of leadership experience in the biopharmaceutical industry, with the likes of Alexion, Roche, and Amgen. He has sage advice to offer about navigating market downturns, while still managing to grow and scale sustainably.
**UPDATE** After recording this interview Keith transitioned from COO to Advisor on the argenx Board of Directors. https://www.globenewswire.com/news-release/2023/03/02/2618906/0/en/argenx-Announces-Planned-Transition-of-Chief-Operating-Officer.html
About argenx
The team at Argenx has created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies. We’ll get more into their discoveries, culture, and how our listeners can bring about innovation by focusing more and more on patients.
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Using Advanced AI to Curate Individualized Cancer Treatments with Navid Alipour, CEO of AI Med Global
From Lab to Launch by Qualio
10/13/22 • 27 min
Today, we are chatting with Navid Alipour. Navid is the founder and CEO of AI Med Global. Navid believes that with consistent advancements in the healthcare industry, the best care is even more accessible than ever before. When treating cancer, Oncologists are attempting to match the best course of treatment to the individual but every cancer is as unique as the patient!
His company, AI Med Global is making curated medicine accessible to cancer patients all over the world. By utilizing genetic information and a cleverly programmed AI, the technology behind CureMetrix and CureMatch are saving lives and improving healthcare.
Listen in this chat with Navid to learn more about how advanced AI is allowing curated individualized treatments for cancer and other exciting progress in the AI and medical industry.
More about Navid:
Navid Alipour is the Chief Executive Officer at AI Med Global, a company focused on Artificial Intelligence Technology that improves healthcare and helps save lives. AI Med Global is a roll-up of two companies Navid cofounded, CureMetrix and CureMatch. He is also a founder of AI focused VC fund, Analytics Ventures. Through the founding of multiple Artificial Intelligence (AI) companies, Navid is a long-time entrepreneur in the AI space with an emphasis on the convergence of AI and the life sciences, which is also called Wellness Science. He seeks to identify scientists and domain experts in their respective fields to that are solving massive pain problems to take to market, by building companies from inception. While he is a VC and part of the founding of Analytics Ventures, he considers himself an entrepreneur at heart.
Links:
https://conquer-magazine.com/issues/2022/vol-8-no-4-august-2022/1895-precision-medicine-might-have-made-a-difference-for-my-mom-it-could-help-patients-with-cancer-today
https://academic.oup.com/jbi/advance-article-abstract/doi/10.1093/jbi/wbac046/6693780?login=false
https://www.linkedin.com/in/navid-alipour-a295777/
https://aimedglobal.com/
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Creating “future proof” antibodies vs. virus variants like Omicron with Ian Chan, co-founder of Abpro
From Lab to Launch by Qualio
01/21/22 • 15 min
Today's guest is Ian Chan the co-founder and executive chairman of Abpro. Abpro is improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Ian explains how their technology is "future proofing" antibodies.
Recently, Abpro announced its ABP 310 COVID antibody retains neutralization activity against the SARS-CoV-2 Omicron variant, which is exciting.
You’ll hear the full story coming up but first some quick takeaways you’ll get from today’s conversation:
- How Abpro is cutting the time to generate antibodies for testing from 1 year to 2 months.
- What all founders should focus on to facilitate fundraising - what Ian calls “first-class science”
- Unique challenges a company faces when it’s in high-growth mode and how to prepare.
More about Ian he co-founded Abpro with his brother, Dr. Eugene Chan, who is the CEO. Not everyone goes into business with family but they’ve done it successfully a few times actually. Ian received an AB from Brown University and MBA from Harvard University.
Show notes:
https://abpro.com/
Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant
Qualio
Apply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Reducing Time to Market for Pharma Companies with Rapid Payer Response and Baiju Aurora, CEO of MAT
From Lab to Launch by Qualio
09/15/21 • 35 min
Typically, it takes several months for third-parties and consultants in the life sciences industry to get data back to pharma companies with payer research. Today's guest is Baiju Aurora, CEO of Market Access Transformation (MAT) is shrinking getting payer response research to a few days.
Baiju has led the MAT team for more than five years and their first product, Rapid Payer Response, provides pharma companies payer research in only a few days from their payer network.
Baiju’s career has spanned pricing, market access, health economics, and outcomes research for bio pharma, medical device, and diagnostics companies.
Key Takeaways:
- Embrace unexpected clients
- Industry trends in pharma, including consolidation, execution, and how faster market research can propel pharma companies forward
- Consider building a company with profitability first in mind rather than scale and growth
Show Notes:
Market Access Transformation (MAT) - Rapid Payer Response
The Physician Payments Sunshine Act
Food Safety Preventive Controls Alliance (FSPCA)
General Data Protection Regulation (GDPR)
European Pharmaceutical Market Research Association (EphMRA)
U.S. Food and Drug Administration (FDA)
Application to be on the show: From Lab to Launch
Music by keldez
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Amazing biotech at high school incubators with Dr. Linnea Fletcher
From Lab to Launch by Qualio
06/28/23 • 24 min
Dr. Linnea Fletcher is a true pioneer at bridging biotech and education. On the show she explains how high school biotech incubators got started and how others can get involved. She also shares more about the upcoming innovATEBIO conference.
Dr. Fletcher she simultaneously joined the first National Science Foundation-funded National Biotechnology Education Center, Bio-Link, and received her first NSF-funded Advanced Technological Education grant to start Biotechnology high school programs in Texas. In 2015, she received an Emerging Technology Fund grant to build a Bioscience Incubator at ACC and several Wagner Peyser grants to equip it. Today, the incubator is full of start-up companies and students interning or working for these companies.
About innovATEBIO
www.innovATEBIO.org
InnovATEBIO, the National Biotechnology Education Center funded by NSF (National Science Foundation). The center was funded 4 years ago at 7.5M for 5 years to coordinate over 134 two-year biotechnology programs and their educational
partners for the purpose of creating a biotechnology workforce focusing on technician education. Every senior scientist needs 5 to 7 technicians for R&D, biomanufacturing and quality assurance and regulatory matters. (National Science Board report 2019). At the moment, there is not enough technicians being produced to meet the needs of the US biotechnology industry.
About Dr. Fletcher
https://innovatebio.org/iab-leadershipDr. Linnea Fletcher enjoys all forms of exercise but especially biking, hiking, and swimming. Her favorite pastimes are family events in the outdoors and travel. She received her Ph.D. in microbiology from the University of Texas at Austin, did two postdocs one at the Southwestern Medical Center and another in the Biochemistry Department at the University of Texas. She joined Austin Community College as a Department Chair in Biology and started the Biotechnology Program in 1999. At the same time, she joined the first NSF Funded National Biotechnology Education Center, Bio-Link and received her first NSF funded ATE grant to start Biotechnology high school programs in Texas. She worked as an NSF Program Officer from
2008 to 2010 and was involved setting up the first Vision and Change Meeting. Once back on the job as Biotechnology Department Chair in 2015, she received an Emerging Technology Fund Grant to build a Bioscience Incubator at ACC and several additional grants to equip it. Today the incubator is full of startup companies and students interning or working for these companies. She was PI of the AC2 Bio-Link Regional Center, and is now the PI of InnovATEBIO, the NSF funded National Biotechnology Center. Combining economic development with educational opportunities is her passion. She is also PI and Co-PI on several other grants associated with the work of the center. Linnea Fletcher believes the best way to engage educate students is to involve them in industry projects from high school on –and show them that their education has a purpose and matters—involvement in startup companies does this!
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
From Hippie to Med School to Entrepreneur with Dr. Hana Solomon, MD
From Lab to Launch by Qualio
12/16/20 • 19 min
If you have a nose, you should check out this episode.
Dr. Hana Solomon, MD shares her journey from hippie to single-mother to med school to entrepreneur. She's the founder of BeWell Health and inventor of Nasopure, the most comfortable nose wash in the world.
She shares her wisdom to avoid "stupid business mistakes" such as acquiring the right type of patent for your product (e.g., design vs. utility patent) and being financially braver to go bigger sooner.
Dr. Hana talks about little things, each of us can do to improve our health. Also at the end, she kindly offers a coupon code to get a discount on her nose wash product.
Guest bio:
Dr. Hana Solomon, MD graduated from the University of Missouri Columbia School of Medicine in 1986 and completed the university's pediatric residency program in 1989. For 20 years Dr. Hana has practiced pediatrics at the Solomon Family Medical Clinic in Columbia, Missouri.
Her articles have been published in the Wall Street Journal, Medscape's webmd.com, About.com, Natural Apathy Digest and other health-related publications. Dr. Hana started BeWell Health in January, 2001. The company's flagship product, Dr. Hana's Nasopure nasal wash systems have helped millions to maintain nasal and sinus health naturally.
Links:
- Nasopure Amazon Store
- www.nasopure.com
- https://www.facebook.com/nasopure.nicer.neti
- Use "QNasopure" coupon code on Amazon
- See more information about From Lab to Launch by Qualio
Music by keldez
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Show more best episodes
Show more best episodes
FAQ
How many episodes does From Lab to Launch by Qualio have?
From Lab to Launch by Qualio currently has 114 episodes available.
What topics does From Lab to Launch by Qualio cover?
The podcast is about Life Sciences, Biotech, Entrepreneurship, Podcasts, Science and Business.
What is the most popular episode on From Lab to Launch by Qualio?
The episode title 'From Emergency Medicine to Disrupting EHR Technology with Dr. Brian Fengler, Co-founder of EvidenceCare' is the most popular.
What is the average episode length on From Lab to Launch by Qualio?
The average episode length on From Lab to Launch by Qualio is 25 minutes.
How often are episodes of From Lab to Launch by Qualio released?
Episodes of From Lab to Launch by Qualio are typically released every 11 days, 17 hours.
When was the first episode of From Lab to Launch by Qualio?
The first episode of From Lab to Launch by Qualio was released on Nov 24, 2020.
Show more FAQ
Show more FAQ